Registrant : Organisation or self-employed individual
| Name/company name: |
F. Hoffmann-La Roche Ltd. |
| Acronym: |
Roche
|
| Legal status: |
Corporation
|
| Website address: |
http://www.roche.com
|
Sections
| Section: |
II - In-house lobbyists and trade/professional associations |
| and more precisely: |
Companies & groups |
Person with legal responsibility
| Surname, Name: |
Mr
Severin Schwan
|
| Position: |
CEO |
Permanent person in charge of EU relations
| Surname, Name: |
Nathalie Stieger
|
| Position: |
Head of Government Affairs |
Contact details:
| Contact details of organisation's head office: |
124 Grenzacherstrasse
Basel 4070
SWITZERLAND
|
| Telephone number: |
(+41) 61 688 11 11 |
| Fax number: |
(+) |
| Other contact information: |
|
Goals / remit
| Goals / remit of the organisation: |
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, infectious diseases, inflammation, metabolism and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2012 Roche had over 82,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 45.5 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
|
|
The organisation's fields of interests are:
|
|
Number of persons engaged in activities falling under the scope of the Transparency Register
| Number of persons: |
7
|
|
Complementary information:
|
|
Persons accredited for access to European Parliament premises
| First name
|
Surname
|
Start Date |
End Date |
|
Nathalie
|
STIEGER
|
16/04/13
|
10/04/14
|
Activities
Main EU initiatives covered the year before by activities falling under the scope of the Transparency Register:
|
- Interactions (direct contacts) with EU Institutions relating to legislation, and implementation of EU regulation at national level;
- Inputting EU Institutions open consultation, including participation in events sponsored by EU Institutions;
- Organisation / sponsoring of information meetings, involving EU Institutions;
- Improve patient safety and strengthen disease prevention in Europe;
- Increase Europe’s competitiveness as a location for Research and Development investment;
- Pharmaceuticals, Diagnostics, Diabetes Care, Intellectual Property, Trade
|
Fields of interest for e-mail alerts on consultations and roadmaps;
| Fields declared by the organisation: |
- Consumer Affairs
- Development
- Enterprise
- Environment
- Internal Market
- Public Health
- Research and Technology
- Trade
|
Networking
Information on (i) organisation's membership of any associations/federations/confederations or (ii) relationships to other bodies in formal or informal networks.
|
Roche is a member of EFPIA, EBE, EDMA, EPPOSI, Kangaroo Group.
|
Financial data
| Financial year: |
01/2012
-
12/2012
|
|
Estimated costs to the organisation directly related to representing interests to EU institutions in that year:
|
450000
€ - 500000
€
|
|
Amount and source of funding received from the EU institutions in financial year n-1 of registration
|
|
Procurement:
|
0 €
|
|
Grants:
|
0 €
|
Other (financial) information provided by the organisation:
|
This estimate is based on the EU Lobbying activities undertaken by various experts within the company as Roche does not have an EU Public Affairs office in Brussels.
|
|
